Shanghai Haohai Biological Technology Co., Ltd. provided preliminary unaudited consolidated group earnings guidance for the year ended 31 December 2023. For the year, the group expects to record a net profit attributable to shareholders of the Company of approximately RMB 400,000,000 to RMB 430,000,000, representing an increase of approximately RMB 219,530,300 to RMB 249,530,300, or approximately 121.64% to 138.27%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company of RMB 180,469,733.31). The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 367,000,000 to RMB 397,000,000, representing an increase of approximately RMB 208,250,400 to RMB 238,250,400, or approximately 131.18% to 150.08%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB 158,749,648.52).